MAP2K7 and cancer: In summary, oncogenic Ras through the MEK/ERK pathway activates LSD1 and increases the binding of the LSD1 corepressor complex to the PIK3IP1 promoter and enhancer to decommission PIK3IP1 activity, which in turn reactivates the PI3K pathway in Ras mutated cancer (Fig. 6b).